Compare PEPG & HIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEPG | HIO |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.9M | 364.2M |
| IPO Year | 2022 | N/A |
| Metric | PEPG | HIO |
|---|---|---|
| Price | $4.89 | $3.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 683.6K | 383.6K |
| Earning Date | 03-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.33% |
| EPS Growth | ★ 25.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.89 | $3.36 |
| 52 Week High | $7.80 | $4.05 |
| Indicator | PEPG | HIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 33.04 |
| Support Level | $4.24 | N/A |
| Resistance Level | $5.50 | $3.91 |
| Average True Range (ATR) | 0.42 | 0.04 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 18.64 | 3.63 |
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.